421P EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC)
Author:
H. Akamatsu,A. Delmonte,T. John,W-C Su,J-S Lee,G-C Chang,X. Huang,S. Jenkins,S. Dearden,Y-L Wu
Publication:
Annals of Oncology
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.